MedPath

Transfer of Large volume of Blood or Blood Products during surgeryâ?? Audit of current practices and post- surgery outcomes

Not Applicable
Conditions
Health Condition 1: C00-D49- Neoplasms
Registration Number
CTRI/2020/07/026654
Lead Sponsor
Tata Memorial Centre
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

All patients undergoing major surgeries with anticipated or unanticipated massive blood loss will be considered eligible.

Exclusion Criteria

-Age less than 18 years.

-Patients who are not willing to participate in the study.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
-To audit current practice of massive blood transfusion management in Tata Memorial Hospital. <br/ ><br>-To evaluate blood transfusion and coagulopathy management during massive blood loss.Timepoint: 1.Preoperative values (if available) -within 2 weeks before surgery. <br/ ><br>2.During surgery. <br/ ><br>3.Before shifting the patient out of the operation theatre. <br/ ><br>4.Immediately after the surgery in the recovery room/ICU. <br/ ><br>5.During the hospital stay.
Secondary Outcome Measures
NameTimeMethod
1. Additional measures used for reducing blood loss such as tranexamic acid, factor 7a, prothrombin <br/ ><br>complex concentrate. <br/ ><br>2. Use of TEG and / or Coagulation profile for correction of coagulopathy. <br/ ><br>3. To evaluate postoperative organ dysfunction. <br/ ><br>4. To evaluate duration of ICU and postoperative hospital stay.Timepoint: 1.During surgery. <br/ ><br>2.Before shifting the patient out of the operation theatre. <br/ ><br>3.Immediately after the surgery in the recovery room/ICU. <br/ ><br>4.During the hospital stay.
© Copyright 2025. All Rights Reserved by MedPath